Cary Street Partners Financial LLC cut its stake in shares of Synopsys, Inc. (NASDAQ:SNPS - Free Report) by 30.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,614 shares of the semiconductor company's stock after selling 2,929 shares during the quarter. Cary Street Partners Financial LLC's holdings in Synopsys were worth $3,107,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also bought and sold shares of SNPS. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Synopsys in the fourth quarter worth $28,000. Oakworth Capital Inc. boosted its position in Synopsys by 3,700.0% during the 4th quarter. Oakworth Capital Inc. now owns 76 shares of the semiconductor company's stock valued at $36,000 after buying an additional 74 shares during the period. KERR FINANCIAL PLANNING Corp purchased a new stake in Synopsys during the 3rd quarter valued at $38,000. N.E.W. Advisory Services LLC grew its holdings in Synopsys by 128.6% in the 4th quarter. N.E.W. Advisory Services LLC now owns 80 shares of the semiconductor company's stock worth $38,000 after acquiring an additional 45 shares during the last quarter. Finally, WealthCollab LLC grew its holdings in Synopsys by 110.8% in the 3rd quarter. WealthCollab LLC now owns 78 shares of the semiconductor company's stock worth $38,000 after acquiring an additional 41 shares during the last quarter. 85.47% of the stock is currently owned by institutional investors.
Synopsys Stock Down 1.6%
Shares of NASDAQ SNPS opened at $525.92 on Thursday. The firm has a fifty day simple moving average of $457.56 and a two-hundred day simple moving average of $453.69. Synopsys, Inc. has a 12 month low of $376.18 and a 12 month high of $651.73. The company has a current ratio of 1.36, a quick ratio of 1.26 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $100.75 billion, a PE ratio of 81.66, a price-to-earnings-growth ratio of 4.38 and a beta of 1.25.
Synopsys (NASDAQ:SNPS - Get Free Report) last announced its earnings results on Wednesday, May 27th. The semiconductor company reported $3.35 earnings per share for the quarter, beating analysts' consensus estimates of $3.15 by $0.20. Synopsys had a net margin of 13.76% and a return on equity of 6.83%. The firm had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.25 billion. During the same quarter in the previous year, the firm posted $3.67 EPS. The company's revenue for the quarter was up 41.9% compared to the same quarter last year. Synopsys has set its FY 2026 guidance at 14.720-14.800 EPS and its Q3 2026 guidance at 3.630-3.690 EPS. Equities analysts expect that Synopsys, Inc. will post 10.28 earnings per share for the current year.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on the stock. Piper Sandler lowered their price objective on shares of Synopsys from $520.00 to $430.00 and set a "neutral" rating for the company in a research note on Thursday, February 26th. Rosenblatt Securities raised their target price on Synopsys from $530.00 to $575.00 and gave the stock a "buy" rating in a research note on Tuesday. Berenberg Bank set a $633.00 price target on Synopsys in a report on Wednesday. Wells Fargo & Company upped their price target on Synopsys from $450.00 to $505.00 and gave the company an "equal weight" rating in a research report on Thursday, May 14th. Finally, Citigroup increased their price objective on Synopsys from $580.00 to $600.00 and gave the stock a "buy" rating in a report on Wednesday, May 13th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $544.88.
Get Our Latest Stock Report on Synopsys
Key Headlines Impacting Synopsys
Here are the key news stories impacting Synopsys this week:
- Positive Sentiment: Synopsys beat Q2 expectations, reporting non-GAAP EPS of $3.35 versus estimates around $3.17 and revenue of $2.276 billion versus consensus near $2.25 billion, showing continued demand for its chip design software. Reuters article
- Positive Sentiment: The company raised FY2026 guidance, now projecting EPS of $14.72 to $14.80 and revenue of roughly $9.6 billion to $9.7 billion, signaling confidence in AI-driven demand and operating momentum. Press release
- Positive Sentiment: Synopsys reached a cooperation agreement with Elliott Investment Management and added Elliott partner Jesse Cohn to its board, which could support efforts to improve margins, governance, and shareholder value. Reuters article
- Neutral Sentiment: Despite the strong report, the stock is reacting cautiously, suggesting some investors may be taking profits after a large run-up and waiting for proof that growth can hold up after the Ansys-related integration and portfolio changes.
- Negative Sentiment: The market may be weighing that Q2 EPS of $3.35 was still below the prior-year $3.67, which can temper enthusiasm even with a beat versus estimates. Zacks article
About Synopsys
(
Free Report)
Synopsys, Inc is a leading provider of electronic design automation (EDA) software and semiconductor intellectual property (IP) used to design, verify and manufacture integrated circuits and complex systems-on-chip (SoCs). Its product portfolio spans tools and technologies for front‑end design and synthesis, simulation and verification, physical implementation and signoff, and design-for-manufacturability, enabling chip designers to move from architecture through tape‑out.
In addition to core EDA offerings, Synopsys supplies a broad set of semiconductor IP building blocks — such as interface, memory and analog/mixed-signal cores — that customers integrate into SoCs to accelerate development.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Synopsys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Synopsys wasn't on the list.
While Synopsys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.